GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
Exosome Diagnostics announces this morning it has raised $27 million and will go to market in 2014 with its first fluid-based diagnostic test, a noninvasive urine sample designed to detect prostate cancer without a biopsy.
Fledgling California diagnostics startup Guardant Health has raised $10 million in a round led by Sequoia Capital. With money in hand, it is gearing up to sell a cancer test that depends on blood samples instead of biopsies, backed by next-generation sequencing.
The controversial 23andMe Personal Genome Test has demonstrated some interesting ancestry numbers, according to a blogger at The Unz Review.
Thorne Research is putting a recent acquisition in personalized medicine to work, partnering its WellnessFX division with blood diagnostics maker Itamar Medical to market a home test for sleep apnea.
One of the elements lacking in the personalized medicine discussion today is the perspective of leading clinicians, informaticists and academics working in the field. To remedy the gap, I've asked a series of leaders in the industry to offer up their views.
Biodesix grabbed $8.3 million in Series E financing to help boost sales and marketing efforts for its personalized medicine-focused lung cancer test.
Narges Bani Asadi, founder and CEO of Bina Technologies By Narges Bani Asadi One of the elements lacking in the personalized medicine discussion today is the perspective of clinicians and...
Sysmex and Bayer struck a deal that takes personalized medicine yet another step forward. The Japanese diagnostics giant and the German drugmaker will develop companion diagnostic tests designed for targeted cancer tumor treatments. Neither side is disclosing financial details, but they'll carry out their agreement through subsidiaries.
Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.